Stock Scorer

Roivant Sciences Ltd. (ROIV)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 03-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 9M 18M 27M Q1 '22: 7.7M Q2 '22: 14M Q3 '22: 24.3M Q4 '22: 9.2M Q1 '23: 4.3M Q2 '23: 12.5M Q3 '23: 17.1M Q1 '24: 21.6M Q2 '24: 3.6M Q3 '24: 15.6M Q4 '24: 9M Q1 '25: 8M Q2 '25: 4.5M Q3 '25: 9M Q4 '25: 7.6M Q1 '26: 2.2M Q2 '26: 1.6M Q3 '26: 2M Q4 '26: 2.5M Q1 '27: 1.4M Q2 '22 Q1 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Operating Income Quarterly

-2B 0 2B 4B 6B Q2 '22: -684.4M Q3 '22: -246M Q4 '22: -266.8M Q1 '23: -282.3M Q2 '23: -280.8M Q3 '23: -378.1M Q4 '23: 34.4M Q1 '24: -276.4M Q2 '24: -213.9M Q3 '24: 5.1B Q4 '24: -206.8M Q1 '25: -102.2M Q2 '25: -341.7M Q3 '25: -274.4M Q4 '25: -285M Q1 '26: -284.9M Q2 '26: -306.2M Q3 '26: -339.2M Q4 '26: 415.2M Q1 '27: -366M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Net Income Quarterly

-2B 0 2B 4B 6B Q2 '22: -208.5M Q3 '22: -284.5M Q4 '22: -270.1M Q1 '23: -331.8M Q2 '23: -291.6M Q3 '23: -352M Q4 '23: -33.6M Q1 '24: -291.8M Q2 '24: -304.3M Q3 '24: 5.1B Q4 '24: -151.1M Q1 '25: 95.3M Q2 '25: -230.2M Q3 '25: 169.4M Q4 '25: -206.5M Q1 '26: -223.4M Q2 '26: -113.5M Q3 '26: -265.9M Q4 '26: 303M Q1 '27: -189.8M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Operating Cash Flow Quarterly

-300M -200M -100M 0 100M 200M 300M Q2 '22: -120.6M Q3 '22: -268.5M Q4 '22: -147.5M Q1 '23: -252.1M Q2 '23: -189.6M Q3 '23: -222.6M Q4 '23: -179.1M Q1 '24: -249.9M Q2 '24: -196.4M Q3 '24: -210.5M Q4 '24: -108.5M Q1 '25: -192.8M Q2 '25: -266.8M Q3 '25: -207.3M Q4 '25: -172.6M Q1 '26: -204.4M Q2 '26: -185.7M Q3 '26: -196.5M Q4 '26: -163.8M Q1 '27: -270.5M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Free Cash Flow Quarterly

-300M -200M -100M 0 100M 200M 300M Q2 '22: -123.4M Q3 '22: -274.6M Q4 '22: -153.7M Q1 '23: -259.5M Q2 '23: -192.7M Q3 '23: -223.1M Q4 '23: -180.7M Q1 '24: -250.3M Q2 '24: -196.7M Q3 '24: -210.8M Q4 '24: -108.8M Q1 '25: -193.8M Q2 '25: -267.8M Q3 '25: -209.1M Q4 '25: -173.4M Q1 '26: -208.4M Q2 '26: -193.5M Q3 '26: -201.4M Q4 '26: -165.1M Q1 '27: -270.9M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 300M 600M 900M Q1 '22: 649.9M Q2 '22: 650.2M Q3 '22: 686.6M Q1 '23: 695.9M Q2 '23: 699.9M Q3 '23: 713.3M Q1 '24: 759.3M Q2 '24: 770.2M Q3 '24: 844.5M Q1 '25: 781.6M Q2 '25: 735.5M Q3 '25: 722.7M Q1 '26: 680.3M Q2 '26: 680.9M Q3 '26: 696.9M Q1 '27: 720.8M Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26 Q1 '27

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.00 0.00 2.00 4.00 6.00 Q2 '22: -1.66 Q3 '22: -1.66 Q4 '22: -1.25 Q1 '23: -1.60 Q2 '23: -1.70 Q3 '23: -1.78 Q4 '23: -1.42 Q1 '24: -1.32 Q2 '24: -1.30 Q3 '24: 5.22 Q4 '24: 5.02 Q1 '25: 5.52 Q2 '25: 5.61 Q3 '25: -0.19 Q4 '25: -0.25 Q1 '26: -0.70 Q2 '26: -0.56 Q3 '26: -1.17 Q4 '26: -0.54 Q1 '27: -0.47 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for ROIV: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.